Youcare Pharmaceutical Group Co., Ltd. (SHA:688658)
China · Delayed Price · Currency is CNY 21.09
-0.11 (-0.52%)
Feb 13, 2026, 3:00 PM CST
SHA:688658 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 2,535 | 3,767 | 4,183 | 4,521 | 4,942 | 4,241 |
Other Revenue | 13.47 | 13.47 | 13.63 | 20.97 | 23.84 | 98.32 |
| 2,548 | 3,781 | 4,196 | 4,542 | 4,966 | 4,339 | |
Revenue Growth (YoY) | -39.77% | -9.90% | -7.61% | -8.53% | 14.45% | 1.20% |
Cost of Revenue | 1,344 | 1,640 | 1,622 | 1,669 | 1,556 | 1,504 |
Gross Profit | 1,204 | 2,141 | 2,574 | 2,873 | 3,410 | 2,835 |
Selling, General & Admin | 976.33 | 1,526 | 1,983 | 2,213 | 2,552 | 2,181 |
Research & Development | 429.71 | 374.31 | 351.88 | 344.42 | 200.03 | 127.89 |
Other Operating Expenses | 25.42 | 32.45 | 38.75 | 54.32 | 63.74 | 51.13 |
Operating Expenses | 1,423 | 1,927 | 2,360 | 2,633 | 2,836 | 2,355 |
Operating Income | -218.89 | 213.69 | 214.88 | 240 | 574.2 | 480.25 |
Interest Expense | -21.78 | -22.4 | -13.21 | -4.7 | -3.47 | -25.07 |
Interest & Investment Income | 5.14 | 17.62 | 23.4 | 28.27 | 35.18 | 2.04 |
Currency Exchange Gain (Loss) | 0.94 | 0.94 | 1.33 | 10.19 | 6.57 | -13.05 |
Other Non Operating Income (Expenses) | -25.51 | -38.64 | -1.24 | -1.08 | -1.18 | -3.5 |
EBT Excluding Unusual Items | -260.09 | 171.22 | 225.15 | 272.68 | 611.3 | 440.67 |
Gain (Loss) on Sale of Investments | 2.65 | 2.34 | -0.69 | 2.89 | - | - |
Gain (Loss) on Sale of Assets | 1.22 | -1.86 | -2.77 | -9.73 | -5.27 | -2.67 |
Asset Writedown | -18.72 | -33.57 | -21.78 | - | -19.17 | - |
Other Unusual Items | 14.23 | 14.23 | 23.36 | 83.68 | 42.41 | 57.13 |
Pretax Income | -260.72 | 152.36 | 223.27 | 349.53 | 629.27 | 495.14 |
Income Tax Expense | -19.17 | 31.11 | 35.77 | 10.62 | 85.55 | 51.51 |
Earnings From Continuing Operations | -241.56 | 121.25 | 187.49 | 338.91 | 543.72 | 443.63 |
Minority Interest in Earnings | 7.57 | 2.47 | -2.7 | -3.72 | 1.59 | -1.49 |
Net Income | -233.99 | 123.72 | 184.8 | 335.18 | 545.32 | 442.14 |
Net Income to Common | -233.99 | 123.72 | 184.8 | 335.18 | 545.32 | 442.14 |
Net Income Growth | - | -33.05% | -44.87% | -38.53% | 23.34% | 54.89% |
Shares Outstanding (Basic) | 443 | 442 | 451 | 453 | 451 | 359 |
Shares Outstanding (Diluted) | 443 | 442 | 451 | 453 | 451 | 359 |
Shares Change (YoY) | -1.33% | -1.97% | -0.49% | 0.51% | 25.37% | -0.52% |
EPS (Basic) | -0.53 | 0.28 | 0.41 | 0.74 | 1.21 | 1.23 |
EPS (Diluted) | -0.53 | 0.28 | 0.41 | 0.74 | 1.21 | 1.23 |
EPS Growth | - | -31.71% | -44.59% | -38.84% | -1.63% | 55.70% |
Free Cash Flow | -41.01 | 79.64 | 288.01 | -669.13 | 314.75 | 570.94 |
Free Cash Flow Per Share | -0.09 | 0.18 | 0.64 | -1.48 | 0.70 | 1.59 |
Dividend Per Share | - | - | 0.200 | 1.100 | 0.680 | 0.450 |
Dividend Growth | - | - | -81.82% | 61.77% | 51.11% | - |
Gross Margin | 47.24% | 56.62% | 61.35% | 63.25% | 68.67% | 65.34% |
Operating Margin | -8.59% | 5.65% | 5.12% | 5.28% | 11.56% | 11.07% |
Profit Margin | -9.18% | 3.27% | 4.40% | 7.38% | 10.98% | 10.19% |
Free Cash Flow Margin | -1.61% | 2.11% | 6.86% | -14.73% | 6.34% | 13.16% |
EBITDA | -2.06 | 409.65 | 383.01 | 394.15 | 709.47 | 611.88 |
EBITDA Margin | -0.08% | 10.84% | 9.13% | 8.68% | 14.29% | 14.10% |
D&A For EBITDA | 216.83 | 195.96 | 168.13 | 154.15 | 135.28 | 131.64 |
EBIT | -218.89 | 213.69 | 214.88 | 240 | 574.2 | 480.25 |
EBIT Margin | -8.59% | 5.65% | 5.12% | 5.28% | 11.56% | 11.07% |
Effective Tax Rate | - | 20.42% | 16.02% | 3.04% | 13.59% | 10.40% |
Revenue as Reported | 2,548 | 3,781 | 4,196 | 4,542 | 4,966 | 4,339 |
Advertising Expenses | - | 4.75 | 14.7 | 18.36 | - | 0.53 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.